FINWIRES · TerminalLIVE
FINWIRES

South Korean Shares Open at New High on Technology Stock Gains

By

South Korean stocks opened at a new high on Monday, led by surging technology shares despite uncertainty around the negotiations between the US and Iran.

The benchmark Korea Composite Stock Price Index, or Kospi, rose 0.1%, or 9.52 points, to open at 8,485.67. The Kosdaq decreased 0.2%, or 2.03 points, to open at 1,072.77.

Major market movers Samsung Electronics (KRX:005930) and LG Electronics (KRX:066570) gained nearly 7% and over 25% in early morning trade, respectively.

Oil prices jumped over 2% on Monday after Israel ordered troops to push deeper into Lebanon, fueling concerns over a broader conflict in the region and potential disturbances to global energy supplies. Brent crude rose 2.1% to $93.05 a barrel, while U.S. West Texas Intermediate (WTI) crude gained 2.5% to $89.53 in early trading.

Related Articles

Asia

MiniMax Explores Shanghai Bourse Listing; Hong Kong Shares Up 5%

MiniMax (HKG:0100) is exploring a proposed listing on the Shanghai bourse's STAR Market, according to a Sunday filing on the Hong Kong bourse.Shares of the artificial intelligence company rose 5% in recent trade.

$^SSEC$^SZSE$HKG:0100
Asia

ASF Group To Sell ASF Coking Coal to Terra Mineral Resources Investment for AU$3.1 Million

ASF Group (ASX:AFA) finalized a share sale and purchase agreement with Terra Mineral Resources Investment for Terra to acquire all issued shares in ASF Coking Coal, a wholly-owned non-core unit, for a cash consideration of AU$3.1 million, according to a Monday Australian bourse filing.ASF Coking Coal holds a portfolio of nine coal tenements in Queensland. The deal is scheduled to be completed within 15 calendar days following the deal's execution date.ASF plans to use the funds from the divestment for future growth initiatives, investment opportunities, and to strengthen its ongoing working capital position.

$ASX:AFA
Asia

CSPC Pharmaceutical Receives $1.2 Billion Upfront Payment From AstraZeneca

CSPC Pharmaceutical (HKG:1093) received $1.2 billion as part of a collaboration and license agreement with AstraZeneca to develop innovative long-acting peptide medicines.The amount represents the upfront payment agreed by both parties when the experimental drugs for obesity and weight-related conditions-focused deal was announced earlier this year, according to a Hong Kong bourse filing on May 29.CSPC is eligible for up to $3.5 billion in development milestones and up to $13.8 billion in sales milestones, and double-digit royalties on net sales.

$HKG:1093